Tata Motors Q2 FY2025: Net Profit Down by 11%, Revenue Falls by 3.5%
Dr. Reddy Labs and Torrent Pharma - Quarterly Results
Last Updated: 8th August 2022 - 06:42 pm
Dr. Reddy's Laboratories reported 11.72% growth in net sales at Rs.4,945 crore for the Jun-21 quarter. However, net profits were down -36% at Rs.380 crore on account of a Rs.184 crore asset impairment write-off in the Jun-21 quarter. Global generics sales were higher yoy but the API business was down. For Reddy Labs, the US accounts for 35% of revenues while India and other emerging markets account for 41%.
Dr. Reddy's Laboratories Quarterly Results
Rs in Crore |
Jun-21 |
Jun-20 |
YOY |
Mar-21 |
QOQ |
Total Income (Rs cr) |
₹ 4,945 |
₹ 4,427 |
11.72% |
₹ 4,768 |
3.71% |
Net Profit (Rs cr) |
₹ 380 |
₹ 595 |
-36.02% |
₹ 557 |
-31.74% |
Diluted EPS (Rs) |
₹ 22.89 |
₹ 35.78 |
₹ 33.51 |
||
Net Margins |
7.69% |
13.43% |
11.69% |
Gross margins at 52.2% was marginally lower than previous quarters. The positive feature of the quarter was R&D expenses at Rs.453 crore or 9.2% of revenues. For the Jun-21 quarter, the EBITDA margins stood at 20.7% while free cash flows (FCF) was at Rs.680 crore. Indian revenues were driven by COVID drug sales. Net margins for Jun-21 quarter stood at 7.69%; lower than 13.43% in Jun-20 quarter and 11.69% in Mar-21 quarter.
Among brokerages, Axis Securities, HDFC Securities and BNP Paribas have upgraded their price target while ICICI Securities had downgraded Reddy Labs to Hold.
Torrent Pharma Ltd reported 3.79% growth in net sales at Rs.2,134 crore for Jun-21 quarter. Net profit for the Jun-21 quarter was up 2.8% at Rs.330 crore on stable EBITDA margins and gross margins in the India business. During the quarter, Torrent Pharma launched anti-COVID drug, Bariticinib, which is currently under clinical trials for Molnupiravir. India revenues were up 18% at Rs.1,093 crore while the US sales were down -29% at Rs.266 crore. Due to price erosion. Germany grew 5%, Brazil 9% while CRAMS vertical grew 6% yoy.
Torrent Pharma Quarterly Results
Rs in Crore |
Jun-21 |
Jun-20 |
YOY |
Mar-21 |
QOQ |
Total Income (Rs cr) |
₹ 2,134 |
₹ 2,056 |
3.79% |
₹ 1,937 |
10.17% |
Net Profit (Rs cr) |
₹ 330 |
₹ 321 |
2.80% |
₹ 324 |
1.85% |
Diluted EPS (Rs) |
₹ 19.53 |
₹ 18.98 |
₹ 19.16 |
||
Net Margins |
15.46% |
15.61% |
16.73% |
Torrent Pharma reported gross margins of 72.4% and EBITDA margins of 34% in the Jun-21 quarter. Till June, Torrent Pharma had 54 ANDAs pending for approval with USFDA with 7 tentative approvals in place. Net margins were 15.46% for Jun-21 quarter compared to 15.61% in Jun-20 quarter and 16.73% in Mar-21 quarter.
Among brokerages, Motilal Oswal and ICICI Securities have upgraded their target for Torrent Pharma while BNP Paribas has downgraded its target.
Trending on 5paisa
05
5paisa Research Team
06
5paisa Research Team
Discover more of what matters to you.
Corporate Actions Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.